Literature DB >> 3279489

Specific toxicologic aspects of the quinolones.

W Christ1, T Lehnert, B Ulbrich.   

Abstract

Possible targets of quinolone toxicity include the juvenile joint, the kidney, the central nervous system (CNS), the eye, and the cardiovascular system. In immature animals all quinolones studied cause arthropathies of the major diarthrodial joints. Arthropathies have also developed in adult dogs after 12 months of pefloxacin treatment. At high doses the quinolones exert effects on renal function that are related to a foreign-body reaction caused by crystals; nephropathologic changes seem not to occur without crystalluria. In humans quinolones can have various CNS effects. The subcellular "substrate" for these effects is unknown. Further understanding of severe CNS reactions (confusion, hallucination, anxiety, agitation, nightmares, convulsive seizures, and depression) is needed. Pefloxacin causes cataracts in dogs after treatment for 8-12 months. Low-dose quinolones (administered as an intravenous bolus) cause pronounced but transient systolic hypotension in dogs and cats; cardiovascular effects may be mediated by histamine release. Quinolones inhibit the bacterial enzyme DNA gyrase. To exclude the possibility of damage to mammalian DNA, mutagenicity studies have been performed. Since all but two tests (which may give false-positive results) have been negative, quinolones appear to be nonmutagenic. Photosensitivity has occurred in humans given quinolones. Drug interactions can be clinically important.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279489     DOI: 10.1093/clinids/10.supplement_1.s141

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  36 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

4.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  The place of quinolones in paediatric anti-infective therapy.

Authors:  J Langley
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

Review 6.  Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Authors:  T D Gootz; J F Barrett; J A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 9.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.